Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Primary IgA Nephropathy Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

NCT03643965
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
Nefecon, Placebo oral capsule
Drug
Lead sponsor
Calliditas Therapeutics AB
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Jul 21, 2026, 10:24 PM EDT
Recruiting Phase 3 Interventional

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

NCT06963827
View directory record Official record
Conditions
Kidney Disease
Interventions
Mezagitamab, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
40
States / cities
Birmingham, Alabama • Montgomery, Alabama • Surprise, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)

NCT04541043
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
Nefecon 16mg daily
Drug
Lead sponsor
Calliditas Therapeutics AB
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 1 Interventional

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

NCT05174221
View directory record Official record
Conditions
Kidney Disease, Glomerulonephritis
Interventions
Mezagitamab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Northridge, California • Nampa, Idaho • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Recruiting Phase 3 Interventional

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

NCT06994845
View directory record Official record
Conditions
Primary Immunoglobulin A Nephropathy (IgAN)
Interventions
iptacopan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Recruiting Phase 3 Interventional

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

NCT06858319
View directory record Official record
Conditions
Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease, Glomerulonephritis, IGA, Glomerulopathy, Immunoglobulin Disease
Interventions
zigakibart
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Denver, Colorado • Orlando, Florida • Clifton Park, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Recruiting Phase 1Phase 2 Interventional

PS-002 for the Treatment of IgA Nephropathy in Adults

NCT07182227
View directory record Official record
Conditions
Immunoglobulin A (IgA) Nephropathy
Interventions
PS-002
Genetic
Lead sponsor
Purespring Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Miami, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Recruiting Phase 4 Interventional

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

NCT06712407
View directory record Official record
Conditions
IgA Nephropathy
Interventions
TARPEYO®
Drug
Lead sponsor
Calliditas Therapeutics AB
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Birmingham, Alabama • Glendale, Arizona • Fresno, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Terminated Phase 2 Interventional

A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

NCT04905212
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Telitacicept 160mg, Telitacicept 240mg, Placebo
Drug
Lead sponsor
RemeGen Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Jul 21, 2026, 10:24 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

NCT05732402
View directory record Official record
Conditions
Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
Povetacicept
Drug
Lead sponsor
Alpine Immune Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 21, 2026, 10:24 PM EDT
Recruiting Phase 2 Interventional

Atacicept in Multiple Glomerular Diseases

NCT06983028
View directory record Official record
Conditions
pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
Interventions
Atacicept
Drug
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Recruiting Phase 3 Interventional

Study of Ravulizumab in Pediatric Participants With Primary IgAN

NCT07024563
View directory record Official record
Conditions
IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis, Henoch-schonlein Purpura Nephritis, IgA Vasculitis
Interventions
Ravulizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Palo Alto, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

NCT03453619
View directory record Official record
Conditions
IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease
Interventions
APL-2
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Stanford, California • Aurora, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Jul 21, 2026, 10:24 PM EDT
Recruiting Phase 2 Interventional

Study of WAL0921 in Patients With Glomerular Kidney Diseases

NCT06466135
View directory record Official record
Conditions
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
Interventions
WAL0921, Placebo
Drug
Lead sponsor
Walden Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
Sefaxersen (RO7434656), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
40
States / cities
Alabaster, Alabama • Birmingham, Alabama • Surprise, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Recruiting Phase 3 Interventional

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

NCT07498335
View directory record Official record
Conditions
Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy, Primary IgAN, Nephritis IgA Type, Nephropathy IgA Type
Interventions
Drug: Atrasentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Neptune City, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 3 Interventional

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

NCT04578834
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Placebo, LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
22
States / cities
Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 21, 2026, 10:24 PM EDT
Active, not recruiting Phase 3 Interventional

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
14
States / cities
Glendale, Arizona • San Diego, California • San Dimas, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 21, 2026, 10:24 PM EDT